Loading...
•
Dec 31, 2023
Nuvation Bio Q4 2023 Earnings Report
Nuvation Bio reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
Key Takeaways
Nuvation Bio reported a net loss of $13.8 million, or $(0.06) per share, for the three months ended December 31, 2023. The company's cash, cash equivalents and marketable securities totaled $611.2 million as of December 31, 2023.
Completed Phase 1 monotherapy study of NUV-868 and determined the MTD.
Phase 1b studies of NUV-868 in combination with olaparib or enzalutamide remain ongoing.
Received FDA clearance of IND application for NUV-1511.
Cash, cash equivalents and marketable securities of $611.2 million as of December 31, 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...